Trastuzumab with chemo for HER2+ bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if adding trastuzumab to standard chemotherapy can help people with advanced bile duct or gallbladder cancer that tests positive for HER2. The study aims to see if the combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have gallbladder or bile duct cancer (not distal cholangiocarcinoma).
- Your cancer is HER2-positive (tested by IHC or FISH).
- You are at least 18 years old.
- You have cancer that cannot be removed by surgery or has spread.
- You have not had chemotherapy for metastatic disease before.
- You have adequate organ function (kidney, liver, blood).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
This study tests a new combination of drugs for advanced bile duct cancer that has not been treated yet and shows a protein called HER2. It compares the new combination to the standard treatment to see if it works better or has fewer side effects.
This trial tests a new combination of drugs for people with HER2-positive bile duct or gallbladder cancer that has grown after first treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.